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Background: CHADS2 or CHA2DS2-VASc score is used for prediction of stroke in patients with atrial ﬁbrillation
(AF). Recently, CHADS2 score is reported to have prognostic value in acute coronary syndromewithout AF. How-
ever, clinical validation of CHA2DS2-VASc score for prognostic stratiﬁcation in coronary heart disease (CHD)with-
out AF remains uncertain. In this study, we evaluatewhether CHA2DS2-VASc score could predict clinical outcome
in CHD without known AF.
Methods: SHINANO registry was a prospective, observational, multicenter cohort study, enrolling 1923 consecu-
tive patients with CHD from August 2012 to July 2013. Two hundred nine patients were excluded because of
known AF. We calculated CHA2DS2-VASc score in the remaining 1714 patients (mean age 70 ± 11 years, 23%
female) without known AF. To assess the clinical validation of CHA2DS2-VASc score, we divided patients into 3
groups according to the tertiles (score 0–2, 3–4, and≥5). The primary endpoint wasMACE including death, non-
fatal myocardial infarction, and ischemic stroke at 1 year.
Results: One-year follow-up was completed in 1632 patients (95.2%). Cumulative incidence of MACE was 139
cases. In Kaplan–Meier analysis, incidence of MACE was signiﬁcantly higher in patients with CHA2DS2-VASc
score ≥5 compared to 3–4 and 0–2 (14.6% vs. 6.8% vs. 5.3%, p b 0.001). In multivariate Cox-regression analysis,
CHA2DS2-VASc score was an independent predictor for MACE (hazard ratio 1.26, 95% conﬁdence interval 1.15–
1.39p b 0.001).
Conclusions: This study demonstrated that CHA2DS2-VASc score could provide prognostic information in CHD
without known AF.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The CHADS2 (congestive heart failure, hypertension, age ≥75 years,
diabetes, ischemic stroke or transient ischemic attack) score is used to
stratify the risk of stroke and to determine whether anticoagulants arey funding agency in the public,
arMedicine, Shinshu University
-0802, Japan. Tel.: +81 263 37
d Ltd. This is an open access article unindicated in patients with atrial ﬁbrillation (AF) [1]. This scoring system
is very familiar to physicians because it could be calculatedwith thedata
frommedical questionnaires.Moreover, the CHADS2 scorewas reported
to have an impact on post-stroke all-cause mortality in patients with or
without AF [2]. It has been also reported that the CHADS2 score could
have prognostic value with regards to adverse outcome in patients
with acute myocardial infarction (MI) [3,4]. Recently, the reﬁned risk
stratiﬁcation for predicting stroke and thromboembolism was assessed
in AF and CHA2DS2-VASc score has been proposed [5]. The CHA2DS2-
VASc score has been assessed its clinical validation compared to
CHADS2 score and several studies conﬁrmed that CHA2DS2-VASc score
was reliable to identify the truly low/high risk patients [6,7]. However,der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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risk stratiﬁcation in patients without known AF undergoing percutane-
ous coronary intervention (PCI).
The aimof this studywas to assesswhether the CHA2DS2-VASc score
could predict the prognosis in patients without known AFwho undergo
PCI.
2. Methods
2.1. Study population
This retrospective cohort study used the data for the period from
August 2012 to July 2013, obtained from the SHINANO (The Shinshu
Prospective Multi-center Analysis for Elderly Patients with Coronary
Artery Disease Undergoing Percutaneous Coronary Intervention)
registry. The design of the SHINANO registry has been described in
detail previously [8]. In brief, the SHINANO registry is a prospective,
multicenter observational registry of patients with any CHD, includ-
ing stable angina, ST-segment elevation MI (STEMI), non-ST-
segment elevation MI (NSTEMI), and unstable angina, undergoing
PCI at 16 collaborating hospitals located in the Nagano Prefecture,
Japan. It has been registered with the University Hospital Medical In-
formation Network Clinical Trials Registry which is accepted by the
International Committee of Medical Journal Editors (UMIN-ID;
000010070). As an all-comer registry, there are no exclusion criteria.
The study protocol was developed in accordance with the Declara-
tion of Helsinki and was approved by the ethics committee of each
participating hospital. All patients gave written informed consent
before participating in this study.
Among the 1923 patients registered in the SHINANO registry, we
identiﬁed 1714 patients without known AF. Patients who had no med-
ical history for AF before revascularization were considered as patients
without known AF in this study. Patients were prospectively followed
for 1 year. The primary endpoint of this study was the incidence of
major adverse cardiac events (MACE) including all-cause death, nonfa-
tal MI, and ischemic stroke.
2.2. Deﬁnitions
The CHADS2 score was calculated for each patient by assigning 1
point each for the presence of congestive heart failure (CHF), hyper-
tension, age≥75 years, or diabetes mellitus and 2 points for a history
of stroke or transient ischemic attack (TIA) [1]. The CHA2DS2-VASc
score was calculated for each patients by assigning 1 point each for
the presence of heart failure (HF)/left ventricular ejection fraction
b40%, hypertension, diabetes, vascular disease, age 65–74 years or
female sex and 2 points for a history of stroke or age ≥75 years [5].
Study patients were divided into 3 groups based on the tertiles of
CHA2DS2-VASc score: low, score 0–2; intermediate, score 3–4;
high, score ≥5. Nonfatal MI was deﬁned as a 2-fold or greater in-
crease in creatine phosphokinase or troponin T levels ≥0.1 ng/ml
or new Qwaves in≥2 contiguous electrocardiogram leads [9]. Ische-
mic stroke was deﬁned as the presence of a new neurological deﬁcit
lasting for at least 24 h with deﬁnite evidence of infarction detected
by magnetic resonance imaging or computed tomography [10]. HF
was based on a previous diagnosis of HF, history of hospitalization
for HF, or current treatment for HF. Diabetes was deﬁned as HbA1C
≥6.5%, fasting plasma glucose ≥200 mg/dl, or oral hypoglycemic or
insulin therapy. Hypertension was deﬁned as systolic blood pressure
(BP) ≥140 mm Hg, diastolic BP ≥90 mm Hg or ongoing therapy for
hypertension. Dyslipidemia was deﬁned as a serum total cholesterol
concentration ≥220 mg/dl, a low-density lipoprotein cholesterol
concentration ≥140 mg/dl, or current lipid-lowering therapy.
Chronic kidney disease (CKD) was deﬁned as an estimated glomeru-
lar ﬁltration rate b60 ml/min per 1.73 m2 calculated using the Mod-
iﬁcation of Diet in Renal Disease formula [11]. Left ventricularejection fraction (LVEF) was assessed with echocardiography using
the Teichholz method, with LVEF ≤40% indicating left ventricular
(LV) systolic dysfunction [12].
2.3. Statistical analysis
Continuous variables are presented as means ± SD, whereas di-
chotomous variables are described as numbers and percentages. Dif-
ferences between the patients in each CHA2DS2-VASc score group
were compared using the chi-square test for categorical variables
and Student's t tests or Wilcoxon rank–sum tests, as appropriate,
for continuous variables. The Kaplan–Meier method was used to as-
sess cumulative mortality or morbidity in the study population. The
log–rank test was used to compare survival curves. Multivariate
Cox regression was performed to identify independent predictors
of MACE in each CHA2DS2-VASc score group. Variables signiﬁcantly
associated with MACE were entered into the multivariate model.
Receiver operating characteristics (ROC) were used to compare the
performance and predictive accuracy of CHA2DS2-VASc score to
CHADS2 score for MACE [13]. Statistical analysis was performed
using the Statistical Package for Social Sciences, version 21 (SPSS
Inc., Chicago, IL, USA) software and statistical package ZER (version
1.27), which is a modiﬁed version of R commander (version 1.6-3)
including statistical functions [14]. A p b 0.05 was considered to indi-
cate statistical signiﬁcance.
3. Results
3.1. Baseline characteristics
Out of 1714 patients, 1632 (95.2%) completed 1 year of follow-up.
Baseline characteristics of the study patients are shown in Table 1.
The mean age of our cohort was 70 ± 11 years. Among the subjects,
22.9% were female, 71.2% had hypertension, 60.4% had dyslipidemia,
37% had diabetes mellitus, 40.8% had CKD, 25.3% had a previous MI,
10.9% had history of HF, 8.3% had a previous stroke, and 8.3% had
LV dysfunction. Regarding lesion characteristics, 54.4% of lesions
were due to acute coronary syndrome (ACS) and 89.2% were de
novo lesions. Patients with a high (≥5) CHA2DS2-VASc score were
more likely to be older and to have more comorbidities, including
hypertension, diabetes, CKD and LV dysfunction, compared to pa-
tients with intermediate (3–4) or low (0–2) CHA2DS2-VASc scores.
Mean SYNTAX score in overall population was categorized into low
SYNTAX group. Patients with a high CHA2DS2-VASc score had higher
SYNTAX score than those with low or intermediate CHA2DS2-VASc
scores.
3.2. Incidence of MACE in overall population
During the follow-up period, the cumulative incidence of MACE was
8.1% (n=139) for the entire study population, including 82 cases of all-
cause death, 35 cases of nonfatalMI, and 22 cases of ischemic stroke. The
incidence of MACEwas signiﬁcantly higher in patients with a high (≥5)
CHA2DS2-VASc score compared to those with an intermediate (3–4) or
low (0–2) CHA2DS2-VASc score (14.6% vs. 6.8% vs. 5.3%, p b 0.001)
(Fig. 1). The details of MACE were also shown in Fig. 1. As CHA2DS2-
VASc score increased, the incidence of all-cause death and stroke was
rising. On the other hand, this trend was not found in the incidence of
myocardial infarction.
To assess the relationship between MACE and CHA2DS2-VASc score,
we performed Kaplan–Meier analysis, which revealed that patients
with a high CHA2DS2-VASc score had a signiﬁcantly higher incidence
of MACE compared to patients with an intermediate or low CHA2DS2-
VASc score (14.6% vs. 6.8% vs. 5.3%, log–rank p b 0.001), as shown in
Fig. 2. Multivariate Cox regression analysis was performed to identify
speciﬁc predictors of MACE in the study population. After adjusting for
Table 1
Baseline characteristics stratiﬁed by CHA2DS2-VASc score.
Variables Overall Score 0–2 Score 3–4 Score ≥5 p
(n= 1714) (n= 643) (n= 659) (n= 412)
Age (years) 69.9 ± 11.1 61.7 ± 9.0 71.7 ± 8.9 80.0 ± 6.8 b0.001
Female 394 (22.9%) 48 (7.4%) 142 (21.5%) 204 (49.5%) b0.001
Body mass index (kg/m2) 23.8 ± 6.6 23.9 ± 4.2 24.4 ± 9.2 22.7 ± 3.9 b0.001
Hypertension 1220 (71.2%) 329 (51.2%) 519 (78.8%) 372 (90.3%) b0.001
Dyslipidemia 1035 (60.4%) 391 (60.8%) 398 (60.4%) 246 (59.7%) b0.001
Low-density lipoprotein cholesterol (mg/dl)
109.7 ± 37.1 119.4 ± 37.5 106.2 ± 33.9 99.9 ± 33.2 b0.001
High-density lipoprotein cholesterol (mg/dl)
48.0 ± 14.6 47.6 ± 12.6 47.8 ± 14.6 49.0 ± 14.9 0.370
Diabetes mellitus 635 (37.0%) 125 (19.4%) 293 (44.5%) 217 (52.7%) b0.001
Hemoglobin A1C (%) 6.4 ± 5.9 6.2 ± 2.3 6.3 ± 1.1 7.4 ± 11.5 b0.001
Current smoker 882 (51.5%) 408 (63.4%) 328 (49.8%) 146 (35.4%) b0.001
Estimated glomerular ﬁltration rate (ml/min/1.73 m2)
62.8 ± 23.5 71.0 ± 20.9 61.2 ± 23.8 52.4 ± 21.7 b0.001
Chronic kidney disease 710 (41.4%) 168 (26.1%) 284 (43.1%) 258 (62.6%) b0.001
Hemoglobin (g/dl) 14.0 ± 6.3 15.0 ± 7.3 14.0 ± 6.6 12.6 ± 2.4 b0.001
Left ventricular ejection fraction at discharge (%)
60.3 ± 16.5 62.0 ± 11.0 60.8 ± 13.7 56.9 ± 15.8 b0.001
Left ventricular dysfunction 142 (8.3%) 17 (2.6%) 56 (8.5%) 69 (16.7%) b0.001
Medical history
Cerebrovascular disease 142 (8.3%) 1 (0.0%) 33 (5.0%) 108 (26.2%) b0.001
Prior coronary artery bypass grafting 132 (7.8%) 29 (4.5%) 50 (7.6%) 53 (12.9%) b0.001
History of heart failure 186 (10.9%) 15 (2.3%) 66 (10.0%) 105 (25.5%) b0.001
Acute coronary syndrome on admission 779 (55.4%) 358 (55.7%) 266 (40.4%) 157 (38.1%) b0.001
De novo lesion 1529 (89.2%) 593 (92.2%) 583 (88.4%) 353 (85.7%) 0.004
In-stent restenosis of drug-eluting stent 75 (4.4%) 22 (3.4%) 37 (5.6%) 16 (3.9%) 0.130
In-stent restenosis of bare metal stent 104 (6.1%) 28 (4.4%) 37 (5.6%) 39 (9.5%) 0.003
Calciﬁcation lesion 483 (28.2%) 122 (18.9%) 198 (30.0%) 163 (39.6%) b0.001
Bifurcation lesion 450 (26.3%) 166 (25.8%) 173 (26.3%) 111 (26.9%) 0.935
Ostial lesion 127 (7.4%) 36 (5.6%) 51 (7.7%) 40 (9.7%) 0.044
Lesion distribution
Left anterior descending artery 807 (47.1%) 315 (48.9%) 301 (45.7%) 191 (46.4%) 0.593
Left circumﬂex artery 325 (18.9%) 114 (17.7%) 132 (20.0%) 79 (19.2%) 0.500
Right coronary artery 632 (36.8%) 237 (36.9%) 243 (36.9%) 152 (36.8%) 0.968
Left main artery 40 (2.3%) 14 (2.2%) 11 (1.7%) 15 (3.6%) 0.101
Bypass graft (saphenous vein graft or internal mammary artery)
5 (0.0%) 1 (0.0%) 4 (1.0%) 0 (0.0%) 0.144
Multi-vessel disease 677 (39.4%) 213 (33.1%) 269 (40.8%) 195 (47.3%) b0.001
SYNTAX score 12.7 ± 8.7 11.8 ± 8.5 12.7 ± 8.3 14.2 ± 9.4 0.004
Medication at discharge
Aspirin 1644 (959.9%) 622 (96.7%) 636 (96.5%) 386 (93.7%) 0.271
Thienopyridines 1533 (89.4%) 587 (91.2%) 599 (90.9%) 347 (84.2%) 0.004
Statins 1221 (71.2%) 492 (76.5%) 461 (69.9%) 268 (65.0%) b0.001
Angiotensin-converting enzyme inhibitors 531 (30.9%) 245 (38.1%) 178 (27.0%) 108 (26.2%) b0.001
Angiotensin receptor blockers 615 (35.9%) 170 (26.4%) 279 (42.3%) 166 (40.3%) b0.001
Beta-blockers 685 (39.9%) 248 (38.7%) 266 (40.4%) 171 (41.5%) 0.527
Warfarin 106 (6.2%) 35 (5.4%) 42 (6.4%) 29 (7.0%) 0.525
Data are shown as mean ± SD or as n (percentages).
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tion of statins at discharge and ACS, CHA2DS2-VASc score was an inde-
pendent predictor of MACE (hazard ratio [HR] 1.26, 95% conﬁdence
interval [CI] 1.15–1.39, p b 0.001) (Table 2).3.3. Comparison of the prognostic signiﬁcance between CHA2DS2-VASc and
CHADS2 score
The CHADS2 score was also evaluated whether it could be an inde-
pendent predictor of MACE in another model using multivariate Cox-
regression analysis. After adjusting gender, presence of CKD, LV dys-
function, multiple coronary artery disease, and ACS, CHADS2 score was
an independent predictor of MACE (HR 1.18, 95% CI 1.10–1.38, p =
0.043).
To compare the predictive accuracy of the CHA2DS2-VASc versus the
CHADS2 score, we described two ROC curves of CHA2DS2-VASc and
CHADS2 score, and then, we compared two areas under the ROC curve
(AUC), shown in Fig. 3. The respective C-statistics for the CHA2DS2-
VASc score and CHADS2 score were 0.64 and 0.59 (p b 0.05).4. Discussion
In the present study, patients with CHD but no known AF and a
CHA2DS2-VASc score ≥5 had a signiﬁcantly higher incidence of MACE
compared to those who with a CHA2DS2-VASc score b5. Our results
indicate that the CHA2DS2-VASc score can be used to identify high-risk
patients undergoing PCI for CHD, even if they have not been diagnosed
with AF.
The CHADS2 and CHA2DS2-VASc score was originally developed for
cardiogenic stroke risk stratiﬁcation in patients with AF. It is a very sim-
ple and convenient scoring system for assessing the complexity of co-
morbidities in patients [1]. A higher score would represent an
independent marker of poor prognosis due to cardiovascular disease
in patients without known AF undergoing coronary angiography [15].
This score could be calculated with information on comorbidities
which is easily obtainable from a medical questionnaire. This scoring
system could be also used for patients with atherosclerotic disease.
Recently, risk stratiﬁcation using the CHADS2 score has been validated
in the patients with ACS [3,4]. However, there have no studies on
using the CHA2DS2-VASc score for risk stratiﬁcation in patients with
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Fig. 1. The 1-year incidence of major adverse cardiac events (MACE) based on the CHA2DS2-VASc score 0–2, 3–4, and ≥5. The incidences of MACE, all-cause death, and stroke were sig-
niﬁcantly higher in patients with CHA2DS2-VASc score ≥5 than those with score 3–4 (chi-square test for linear trend p b 0.05). This trend was not observed between the patients with
CHA2DS2-VASc score 0–2 and the patients with CHA2DS2-VASc score 3–4.
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undergoing PCI.
In this study, we demonstrated that the CHA2DS2-VASc score had
predictive value for adverse outcomes in patients with CHD undergoing
PCI, even in patients with no known AF. This result was consistent withat risk
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Fig. 2. Kaplan–Meier analysis of major adverse cardiac events (MACE) by CHA2DS2-VASc
score in the overall study population. In patients with a CHA2DS2-VASc score≥5, the inci-
dence ofMACEwas signiﬁcantly higher than in thosewith a CHA2DS2-VASc score of 3–4 or
0–2 (14.6% vs. 6.8% vs. 5.3%, log–rank p b 0.001).previous reports on the prognostic value of the CHADS2 score in acute
MI [3]. Moreover, the comparison of predictive accuracy between
CHA2DS2-VASc and CHADS2 score revealed that the CHA2DS2-VASc
score had more powerful predictive value for MACE than that of
CHADS2 score. In the present study, we excluded 209 of 1923 patients
(10.8%) in the SHINANO registry who had documented AF. In general,
no more than 20% of patients who require PCI have concomitant AF
[16]. The proportion of AF in the SHINANO registry was similar to that
in recent statement; therefore, our results may be representative of
the general population.
Each of the components of the CHA2DS2-VASc score has been report-
ed as an independent predictor of adverse outcomes in the general pop-
ulation; this was one reason why there was an association between the
CHA2DS2-VASc score andMACE in our study cohort. In developed coun-
tries, the prevalence of HF is approximately 1% to 2%, but rises to over
10% among individuals 70 years or older [17]. Before 1990, 60% to 70%
of patients with HF died within 5 years of diagnosis in many countriesTable 2
Multivariate analysis of MACE in the overall study population.
Variable HR 95% CI p
Estimated GFR 0.99 0.98–0.99 0.011
Acute coronary syndrome 1.69 1.18–2.42 0.004
Administration of aspirin 0.41 0.20–0.86 0.017
Administration of statin 0.73 0.50–1.07 0.101
CHA2DS2-VASc score 1.26 1.15–1.39 b0.001
Themodel included CHA2DS2-VASc score, an estimate glomerular ﬁltration rate (ml/min/
1.73 m2), acute coronary syndrome on admission, an administration of aspirin at
discharge, and an administration of statin at discharge.
MACE, major adverse cardiac event; HR, hazard ratio; CI, conﬁdence interval.
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Fig. 3. Receiver operating characteristic (ROC) curves for CHADS2 and CHA2DS2-VASc
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morality, but the high incidence of mortality in HF remains an issue of
concern [19]. The proportion of hypertension in the general population
appears to be approximately 30% to 45% and increases with age [20]. A
large number of observational studies have demonstrated an indepen-
dent continuous relationship between blood pressure and the incidence
of several cardiovascular events (stroke, MI, and sudden death) in all
age groups and all ethnic groups [21]. Elderly patients potentially have
an increased risk of mortality; older age has been reported as an inde-
pendent predictor of atherosclerosis and cardiovascular events [22].
Both diabetes mellitus and disorder of glucosemetabolic are risk factors
for cardiovascular disease. High 2 h post-load plasma glucose predicts
all-cause and cardiovascular disease mortality after adjusting for other
major cardiovascular risk factors. There is a high reported absolute
risk of MI or vascular death after ischemic stroke [23,24]. In recent
study, patients with atherosclerotic disease are at increased risk of is-
chemic events in systemic vascular beds, including cardiovascular
death, MI or stroke. Moreover, these event rates increased with the
symptomatic vascular disease location [25]. Sex disparity in survival
has been documented in several studies and women have higher mor-
tality than men in CHD [26].
The clinical beneﬁt of the CHA2DS2-VASc score in risk stratiﬁcation
for patients undergoing PCI is its simplicity. Only simple addition is
needed to calculate CHA2DS2-VASc score without complex equations.
We could stratify each patient undergoing PCI based on the CHA2DS2-
VASc score, especially patients with a CHA2DS2-VASc score ≥5, which
is considered high-risk.
There were several limitations in this study. First, the identiﬁcation
of patients without known AF was based on past medical records, med-
ical questionnaires, and electrocardiogrammonitoring during hospital-
ization. We did not assess the incidence of AF by ambulatory
electrocardiography during the follow-up period. Henriksson et al.
reported that the CHADS2 score had an impact on all-cause mortality
after stroke in patients with or without AF [2]. Therefore, our data
might not change drastically if our patients were diagnosed AF during
follow-up. Second, more than 75% in our population was male; there-
fore our results may not be applied to general population. However,
since our study was based on observational registry data, we thought
that this represented a real-world unselected population of patientswith CHD undergoing PCI. Nevertheless, in patients undergoing PCI,
the CHA2DS2-VASc score could provide prognostic information even if
they were not known to have AF. A further longer follow-up study is
required to evaluate the long-term impact of the CHA2DS2-VASc score
in patients without known AF who undergo PCI.
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